Form 4: Orthofix Medical Director Michael Paolucci Receives Deferred Stock Unit Award

Orthofix Medical Inc. Director Michael E. Paolucci was granted 18,841 deferred stock units, increasing his beneficial ownership to 86,948 shares.

Summary

• Orthofix Medical Inc. (OFIX) Director Michael E. Paolucci acquired 18,841 shares of common stock on June 18, 2025, through an award of deferred stock units.
• These deferred stock units (DSUs) vest in full on the first anniversary of the grant date, contingent upon Mr. Paolucci's continued service.
• Each DSU represents a contingent right to receive one share of Orthofix common stock.
• Vested DSUs will settle and convert into common stock within 45 days of Mr. Paolucci's termination of service with the issuer.
• Following this transaction, Mr. Paolucci's total beneficial ownership in Orthofix Medical Inc. stands at 86,948 shares.
• The total beneficial ownership includes 54,700 previously reported deferred stock units and 1,341 shares acquired under Orthofix's Stock Purchase Plan on October 31, 2024.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates a director's equity compensation and aligns their interests with shareholders, which is a standard corporate governance practice.

Positives

• The award of deferred stock units to a director aligns the director's interests with those of the shareholders, as the value of the award is tied to the company's stock performance.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects.

Future Outlook

The document indicates future vesting of deferred stock units on the first anniversary of the grant date, contingent on continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in the medical device industry and across publicly traded companies, reflecting a component of executive and director compensation.

Related Party Transactions

• The award of deferred stock units to Director Michael E. Paolucci constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The award of equity to a director helps align their financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The 18,841 deferred stock units are expected to vest on the first anniversary of the grant date (approximately June 18, 2026), subject to the director's continued service.
• Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.

Key Dates

Keywords

Orthofix Medical Inc., OFIX, SEC Form 4, Insider Transaction, Deferred Stock Units, Director Compensation, Stock Award, Beneficial Ownership